San Diego, CA, September 27, 2023 /PR NEWSWIRE/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced the first patient dosed in the Phase 1a/b study of ADRX-0706 for the treatment of advanced solid tumors.“We are pleased...Continue reading
Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors
First asset utilizing Adcentrx’s ADC platform to receive IND clearance Planned Phase 1a/1b clinical trial expected to begin in 2H 2023 SAN DIEGO, July 17, 2023 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, today announced that the...Continue reading
AvantGen Appoints Jordon Wang as Chief Operating Officer
AvantGen, a San Diego based biotechnology company with a superior yeast display technology for facile...Continue reading
A Novel BCMA Immunohistochemistry Assay Reveals a Heterogenous and Dynamic BCMA Expression Profile in Multiple Myeloma
Abstract B-cell maturation antigen (BCMA) is a promising target for the treatment of multiple myeloma (MM) because the expression of this protein is largely limited to B-cell sets, plasma cells, MM, and other B-cell malignancies. Early studies assessing BCMA protein expression and localization have used insufficiently qualified immunohistochemistry assays, which...Continue reading
AvantGen awarded contract from NIH to expedite the commercialization of its AccuRate COVID-19 SelfCheck OTC test
AvantGen, a San Diego based biotechnology company with a superior yeast display technology for facile...Continue reading
Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug Conjugates
SAN DIEGO, Feb. 14, 2022 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a biotechnology...Continue reading
AvantGen receives an award from the NIH/RADx to commercialize its anti-SARS-CoV-2 nucleocapsid antibodies for ultra-high sensitivity lateral flow assay development
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) — AvantGen, a San Diego-based biotech, is a leader...Continue reading
High-throughput screening and validation of antibodies against synaptic proteins to explore opioid signaling dynamics
Abstract Antibodies represent powerful tools to examine signal transduction pathways. Here, we present a strategy integrating multiple state-of-the-art methods to produce, validate, and utilize antibodies. Focusing on understudied synaptic proteins, we generated 137 recombinant antibodies. We used yeast display antibody libraries from the B cells of immunized rabbits, followed by...Continue reading
AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
SAN DIEGO–(BUSINESSWIRE)–AvantGen, Inc., a San Diego-based biotechnology company with an...Continue reading
A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters
Abstract The emergence of COVID-19 has led to a pandemic that has caused millions of cases of disease, variable morbidity and hundreds of thousands of deaths. Currently, only remdesivir and dexamethasone have demonstrated limited efficacy, only slightly reducing disease burden, thus novel approaches for clinical management of COVID-19 are needed....Continue reading